Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors
This phase III trial studies the effect of tenofovir alafenamide in preventing liver complications in patients with current or past hepatitis B virus (HBV) who are receiving anti-cancer therapy for solid tumors. People with chronic or past HBV who are undergoing therapy for cancer are at an increased risk for changes in the liver which could be minor or severe. Tenofovir alafenamide is a drug that acts against infections caused by HBV and may help reduce the chance that HBV gets worse or comes back in patients receiving anti-cancer therapy for solid tumors.
Research Base: Southwest Oncology Group
NCT ID: NCT03887702
NCI Protocol Number: SWOG-S1614
Status: Recruiting
For more information see ClinicalTrials.gov
Interventions
- Entecavir
- Tenofovir Disoproxil Fumarate
- Best Practice
- Tenofovir Alafenamide
Condition
Hepatitis B Infection, Malignant Solid Neoplasm
Trial Type
Supportive Care/Symptom Management/PROs
See a list of participating sites on ClinicalTrials.gov